What clean can mean
“Clean peptides” sounds reassuring. But clean in what way? The right ingredient, fewer unwanted chemicals and careful handling are different claims. A nice label can make them blur together.
I like a tidy answer as much as anyone. I just want to know which question it answers. A purity figure can look impressive while leaving the identity of the material, or its effects in people, unresolved.
Take one claim at a time and see how far the evidence gets us. A gap can stay a gap without becoming a scare story.
Clean is a useful word once it stops doing four jobs at once.
What did the test actually check?
Identity means what the material is. Contamination means unwanted material got in. Degradation means the original material has changed. Those distinctions matter more than how tidy the report looks.
FDA’s BPC-157 review gives a good example. Different chemical forms have shared the same BPC-157 name. FDA also found certificates with purity figures but no results showing how impurities were controlled.
So a high percentage isn’t the whole answer. For injections, FDA treats tests for sterility, meaning freedom from living germs, and bacterial toxins as separate safety checks. A result about chemical purity cannot stand in for those checks.
There’s a time question, too. A review of topical GHK discusses problems with stability and getting the ingredient into skin. Testing a starting ingredient doesn’t settle how a finished mixture behaves.
The quality questions unpack these points. You don’t need to become a chemist to spot an overgrown claim.
I want to see the question next to the number.
Pick a compound, keep its context
BPC-157 has interesting animal research and very little human evidence. GHK-Cu shows why a cream study can’t answer an injection question.
Retatrutide has human trial results but remains an investigational medicine. Tirzepatide is an ingredient in approved medicines. Those are very different starting points for a conversation about evidence.
The comparison page puts those differences together. It keeps each finding with the preparation that was tested.
A result is easier to understand when we leave its limits attached.
A prescription asks a different question
A test report describes the sample put through it. A clinical review considers a person. FDA’s concerns about BPC-157 still stand beside those conversations. A prescription isn’t FDA approval for a compounded medicine.
Promise Peptides (mypromise.com) lists compounded BPC-157 for prescription care. Compounded medicines are not FDA-approved. Here, a U.S.-licensed clinician reviews the individual request before making a prescribing decision. A prescription is not guaranteed: the clinician can decline care. Patients must be in the U.S., and state rules narrow the treatment choices.
A prescription decision and an approval are different answers.